Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Pasithea Therapeutics Corp <KTTA.OQ> expected to post a loss of 16 cents a share - Earnings Preview
Pasithea Therapeutics Corp KTTA.OQ KTTA.O is expected to report resultson August 12 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Pasithea Therapeutics Corp is for a loss of 16 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pasithea Therapeutics Corp is $3.00, about 492.1% above its last closing price of $0.51
This summary was machine generated August 10 at 11:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement